[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"b-cell-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:b-cell-neoplasm":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100469178","phase-1-pomalidomide-and-dose-adjusted-epoch---rituximab-for-hiv-associated-lymphomas-100469178",false,"NCT05389423","Pomalidomide and Dose-Adjusted EPOCH +\u002F- Rituximab for HIV-Associated Lymphomas","Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +\u002F- Rituximab for HIV-Associated Lymphomas","* INCLUSION CRITERIA:\n* Histologically or cytologically confirmed B-cell NHL confirmed by the Laboratory of Pathology (LP), NCI, with one or more of the following features:\n\n  * Leptomeningeal\u002FCSF involvement\n  * High-risk for CNS relapse per CNS-IPI (score 4-6)\n  * Plasmablastic histology\n  * Gamma herpesvirus positive tumor\n  * Presence of KS\n* Measurable or evaluable lymphoma.\n* Positive HIV1\u002F2 serology.\n* Individuals may not have received prior curative-intent chemotherapy for lymphoma. Individuals who have received prior treatment as a bridge to curative-intent therapy will be considered per Protocol Chair discretion if \\>= 2 weeks since administration. Steroids given for any reason or rituximab given for multicentric Castleman disease may be given any time prior to treatment start.\n* Age \\>=18 years\n* Eastern Cooperative Oncology Group performance status (ECOG-PS) \\\u003C=4\n* Individuals of childbearing potential (IOCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU\u002FmL within 2 weeks prior to and again within 1 day before starting the study drugs and must either commit to continued abstinence from penetrative vaginal intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before the participant starts taking pomalidomide and for 12 months after the last dose of combined chemotherapy.\n* Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to six (6) months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask the partners to be on an effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.\n* All individuals must agree to be registered into the mandatory POMALYST REMS(R)TM program and be willing and able to comply with the requirements of the POMALYST REMS(R)TM program.\n* Able to take aspirin 81mg orally daily or another substitute thromboprophylaxis.\n* Adequate organ and marrow function as defined below unless abnormalities are attributed to lymphoma or HIV as determined by investigator:\n\n  * absolute neutrophil count \\>=1,000\u002FmcL\n  * platelets \\>=75,000\u002FmcL\n  * total bilirubin \\\u003C=1.5 X institutional upper limit of normal (individuals with history of Gilbert disease are eligible if total bilirubin \\\u003C= 5 mg\u002FdL with \\\u003C80% unconjugated bilirubin)\n  * aspartate aminotransferase (AST) \u002F alanine transaminase (ALT) \\\u003C=3 X institutional upper limit of normal\n  * creatinine clearance \\>=60 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal.\n* Hepatitis B virus (HBV) infection must be on suppressive antiviral therapy.\n* Willingness to take and adhere to ART (individuals are not required to be on any specific regimen of ART).\n* Individuals must understand and sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Individuals may not receive investigational agents on other clinical trials.\n* Requirement of any of the agents listed as prohibited thearapies.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide or other agents used in study.\n* Parenchymal brain involvement with lymphoma.\n* Ejection fraction less than 40% by echocardiography (ECHO)\n* CTCAEv5.0 Grade 3-4 neuropathy\n* History of malignant tumors other than KS or KSHV-associated multicentric Castleman Disease, (MCD), unless:\n\n  * In complete remission for \\>= 1 year from the time response was first documented; or,\n  * Completely resected basal cell carcinoma; or,\n  * In situ squamous cell carcinoma of the cervix or anus; or,\n  * Prior or concurrent malignancy has a natural history or treatment which does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen per Protocol Chair discretion.\n* Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome.\n* Symptomatic congestive heart failure\n* Unstable angina pectoris, symptomatic cardiac arrhythmia, or cardiac arrhythmia requiring medical treatment.\n* Uncontrolled intercurrent illness or participants considered to be of poor medical health due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active uncontrolled infection (excluding lymphoma or HIV) as documented in prior records or suggested by medical history, physical examination or standard clinical assessments such as imaging and laboratory studies.\n* Pregnant or nursing individuals (if lactating, must agree not to nurse while taking pomalidomide).","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Background:\n\nNon-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating\n\npeople with both HIV and NHL.\n\nObjective:\n\nTo test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL.\n\nEligibility:\n\nAdults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features.\n\nDesign:\n\nIndividuals will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans. Researchers will review tissue samples of individual s tumors. In some cases, a new biopsy may be needed.\n\nIndividuals will receive up to 6 cycles of treatment.\n\nThe first cycle is 26 days: Individuals will take pomalidomide by mouth for 10 days. After 5 days they will start receiving chemotherapy drugs through a tube attached to a needle placed in a vein (IV). Some participants will receive rituximab on day 5. All individuals will receive a second set of IV drugs that will last for 4 days (96 hours). They will receive another IV drug after the previous treatment is complete.\n\nThe remaining cycles are each 21 days. Individuals will take pomalidomide by mouth for the first 10 days. Other chemotherapy treatments will also be repeated starting on day 1 of each cycle.\n\nScreening tests will be repeated at study visits.\n\nFollow-up visits will continue for 4 years....",[26,27,28,29,30],"Diffuse Large Cell Lymphoma","Non-Hodgkin Lymphoma","Burkitt Lymphoma","Plasmablastic Lymphoma","B-Cell Neoplasm",[27,32,29,33,34],"Epstein Barr Virus","Chemotherapy","Immune Modulatory","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2023-06-27",{"date":43,"type":20},"2032-06-01",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100555195","phase-2-safety-and-efficacy-study-of-zamtocabtagene-autoleucel-mb-cart20191-in-pediatric-patients-with-rr-b-cell-neoplasms-100555195","NCT06508931","Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R\u002FR B-Cell Neoplasms","A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed\u002FRefractory Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease","DALY PED","Inclusion Criteria:\n\n1. Is able to provide age-appropriate assent\u002Fconsent (as applicable, according to local legislation) and\u002For have a guardian able to provide consent signed and dated by the parent(s) or by subject's legal guardian before conduct of any study-specific procedures.\n2. Has histologically confirmed mature CD19+ and\u002For CD20+ B-cell neoplasm such as:\n\n   * Burkitt lymphoma\u002FBurkitt leukemia\n   * Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)\n   * Primary mediastinal (thymic) large B-cell lymphoma\n   * Burkitt-like lymphoma with 11q aberration\n   * Aggressive mature B-cell lymphoma\n   * Other rare aggressive B-cell non-Hodgkin lymphoma (NHL) after sponsor approval.\n3. Has r\u002Fr B-cell neoplasms after one or more prior therapies or primary refractory to first-line therapy.\n4. Is a pediatric\u002Fadolescent (aged between 6 months and \\\u003C18 years).\n5. Has a BW of ≥ 6 kg.\n6. Measurable disease based on the International Pediatric NHL Response Criteria (which refers to the Lugano criteria for definitions of measurability and selecting index lesions), as identified by local radiological assessment for lymphomas. Previously irradiated lesions cannot be considered measurable unless the lesion has proven radiological evidence for progression after the radiation.\n7. Tissue samples archival or fresh (preferred) from recent relapse or initial diagnosis (in case of primary refractory disease) must be made available for the central pathology review to confirm diagnosis (≤2 years, preferably not older than 2 months since collection).\n8. Has Karnofsky (aged ≥16 years) or Lansky (aged \\\u003C16 years) performance status ≥60.\n9. Has adequate bone marrow function as defined by the following laboratory values (as assessed by local laboratory for eligibility):\n\n   * Absolute neutrophil count (ANC) \\>1000\u002FμL.\n   * Platelets ≥50000\u002FμL.\n   * Hemoglobin ≥8.0 g\u002FdL.\n   * Absolute lymphocyte count ≥100\u002FμL.\n10. Has adequate organ function as follows:\n\n    * Renal function: estimated glomerular filtration rate (eGFR) \\>29 mL\u002Fmin by Schwartz formula (Schwartz et al 1976).\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 × upper limit of normal (ULN) for age.\n    * Bilirubin \\\u003C1.5 x ULN (for Gilbert's Syndrome, subject's total bilirubin \\\u003C4 mg\u002FdL).\n    * Adequate pulmonary function as follows:\n\n      * Resting oxygen saturation of ≥91% on room air.\n      * No or mild dyspnea (Grade ≤1).\n11. Female subjects of childbearing potential must be willing to undergo pregnancy tests before MB-CART2019.1 infusion.\n12. If subjects are sexually active, they must be willing to use highly effective methods of contraception.\n\n    * Female subjects must agree to use two methods of contraception;\n\n      * one of the following methods (Pearl index \\\u003C1%): Hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, injected, implanted, transdermal), intrauterine devices (IUDs) or systems (e.g., hormonal and non-hormonal IUD), or vasectomized sexual partner AND one barrier method.\n      * Highly effective methods of contraception must be followed from inclusion until 12 months after MB-CART2019.1 infusion.\n    * Male subjects must agree to use a condom during intercourse from inclusion through at least 12 months after MB-CART2019.1 infusion to prevent them from fathering a child AND to prevent delivery of MB-CART2019.1 via seminal fluid to their partner. Do not use a female condom when using a male condom, since tearing can occur. In addition, male subjects must not donate sperm for the time period specified above.\n    * Females must agree not to breast feed or donate eggs\u002Fova during the study and until at least 12 months after MB-CART2019.1 infusion.\n13. Is willing to undergo collection of non-mobilized leukapheresis.\n14. In the opinion of the investigator, the subject must be able to comply with all study-related procedures, medication use, and assessments.\n\nExclusion Criteria:\n\n1. Is receiving active treatment for malignant disease (including participation in any additional parallel investigational drug or device studies), except for pre-enrollment therapy, including radiotherapy. Lesions that are irradiated during pre-enrollment therapy may not be considered measurable lesions. For subjects with lymphoma to be eligible, there must be at least one measurable lesion after pre-enrollment therapy.\n2. Had allogeneic HSCT.\n3. Had autologous HSCT \\\u003C120 days prior to written informed consent.\n4. Had major surgery within 2 weeks before leukapheresis, or has not fully recovered from an earlier surgery, or has major surgery planned during the time the subject is expected to participate in the study.\n5. Subjects with B-cell neoplasms in the context of post-transplant lymphoproliferative disorders-associated lymphomas.\n6. Has known hypersensitivity to the excipients of the MB-CART2019.1 or to any other drug product as advised for administration in the study protocol (e.g., lymphodepleting agents).\n7. Has active central nervous system (CNS) involvement at the time point of eligibility confirmation, as measured by the presence of lymphoma cells in cerebral spinal fluid (CSF) on cytospin preparation.\n8. Has history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis, or other immunologic or inflammatory diseases.\n9. Infection with human immunodeficiency virus (HIV).\n10. Presence of active or prior hepatitis B or C as indicated by serology. Treated infection with hepatitis B or C virus unless confirmed to be polymerase chain reaction (PCR) negative.\n11. Has infection with Treponema pallidum.\n12. Has active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n13. Has infection with human T-lymphotropic virus 1\u002F2 (HTLV 1\u002F2).\n14. Has active severe systemic fungal, viral, or bacterial infection, requiring systemic antiviral, antifungal, or antimicrobial therapy.\n15. Has clinically significant seizures according to the opinion of by the investigator.\n16. Has history of cerebral vascular accident within 12 months prior to leukapheresis.\n17. Has impaired cardiac function: Fractional shortening \\\u003C28% or left ventricular ejection fraction \\\u003C50% by echocardiography or multigated acquisition, if allowed as per local law.\n18. Has concomitant genetic syndromes associated with bone marrow (BM) failure status, such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known BM failure syndrome.\n19. Is a pregnant or breast-feeding female.\n20. Is sexually active and not willing to use highly effective methods of contraception as described in the inclusion criteria.\n21. Has history of another malignancy within the prior 3 years that required systemic therapy.\n22. Has other medical, psychological, or social condition that, in the opinion of the investigator, would impact subject safety or confound the study results.\n23. Has received vaccination with live virus within 6 weeks prior to informed consent.\n24. Has been previously treated with approved anti-CD19 or anti-CD20 CART cell therapies \\\u003C100 days prior to informed consent\u002Fassent.","6 Months","17 Years",{"count":59,"type":20},31,[61],"PHASE2","This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \\\u003C18 years, ≥6 kg body weight \\[BW\\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.",[30],"2026-05-04",{"date":66,"type":39},"2026-05-05",{"date":68,"type":39},"2025-08-04",{"date":70,"type":20},"2029-12-31",{"name":72,"class":73},"Miltenyi Biomedicine GmbH","INDUSTRY",5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100581224","systemic-inflammatory-markers-in-b-cell-neoplasm-100581224","NCT06847529","Systemic Inflammatory Markers in B-cell Neoplasm","Systemic Inflammatory Markers As a Prognostic Index for B-cell Neoplasm , Single Center Experience .","Inclusion Criteria:\n\n* Individuals newly diagnosed with B-cell neoplasms, including:\n* Burkitt's lymphoma (BL)\n* Chronic lymphocytic leukemia (CLL)\n* Diffuse large B-cell lymphoma (DLBCL)\n* Follicular lymphoma (FL)\n* Hairy cell leukemia (HCL)\n* Splenic B-cell lymphoma\u002Fleukemia with prominent nucleoli (SBLPN)\n* High-grade B-cell lymphoma (HGBL)\n* Lymphoplasmacytic lymphoma (LPL)\u002FWaldenström macroglobulinemia\n* Mantle cell lymphoma (MCL)\n* Splenic marginal zone lymphoma (MZL)\n* Monoclonal B-cell lymphocytosis (MBL)\n* Multiple myeloma (plasma cell myeloma)\n* Monoclonal gammopathy of undetermined significance (MGUS)\n* Age 18 years or older.\n\nExclusion Criteria:\n\n* Individuals previously diagnosed with B-cell neoplasms.\n* Individuals younger than 18 years.",{"count":83,"type":20},70,"OBSERVATIONAL","This study was to evaluate the role of systemic inflammatory markers in predicting outcome for patients with B cell neoplasm",[87],"B-cell Neoplasm",[89],"Systemic inflammatory markers as a prognostic index","NOT_YET_RECRUITING","2025-03-09",{"date":93,"type":39},"2025-03-12",{"date":95,"type":20},"2025-03-22",{"date":97,"type":20},"2025-12-30",{"name":99,"class":100},"Assiut University","OTHER"]